HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.19356-17-3
| CALCIFEDIOL Basic information |
| Product Name: | CALCIFEDIOL |
| Synonyms: | CALCIDIOL;25-HYDROXYVITAMIN D3;25-HYDROXYCHOLECALCIFEROL;VITAMIN D3, 25-HYDROXY-;25-HYDROXYVITAMIN D3 WHITE CRYSTALLINE SOLID 985;25-Hydroxyvitamin D3;vitamin d3 25-hydroxy monohydrate;(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol |
| CAS: | 19356-17-3 |
| MF: | C27H44O2 |
| MW: | 400.64 |
| EINECS: | 242-990-9 |
| Product Categories: | Vitamin D3 analogs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Isolabel;Inhibitors |
| Mol File: | 19356-17-3.mol |
|
|
|
| CALCIFEDIOL Chemical Properties |
| mp | 74-76oC |
| Fp | 14 °C |
| storage temp. | −20°C |
| Safety Information |
| Hazard Codes | T+,F |
| Risk Statements | 28-48/25-26-24/25-11 |
| Safety Statements | 28-36/37-45-16-7 |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| F | 8-10-19 |
| MSDS Information |
| Provider | Language |
|---|---|
| SigmaAldrich | English |
| CALCIFEDIOL Usage And Synthesis |
| Therapeutic drug for bone disease |
The natural source of Vitamin D in the body depends on ultraviolet rays of sunlight, making the 7- dehydrocholesterol convert into vitamin D3, at first under the action of vitamin D3 hydroxylase in liver vitamin D3 converts into the Calcifediol, vitamin D3 mainly is present in the form of the Calcifediol in the blood, in the kidney the Calcifediol is further converted to 1,25-dihydroxyvitamin D3 (calcitriol for short) and 24,25-dihydroxyvitamin D3, activity of calcitriol is 2-5 times of the Calcifediol, the two drugs can promote bone re-absorption of calcium and intestinal absorption of Ca2 +. In addition to regulating the body's calcium and phosphorus metabolism, this product can promote the intestinal absorption of calcium and phosphorus, promote calcium and phosphorus deposits in the bone tissue, promote bone formation. Calcifediol itself has a certain activity, can be used for the treatment of metabolic bone diseases, such as osteoporosis, rickets, osteomalacia, but also for hemodialysis-induced hypocalcemia. Patients with chronic renal failure combined with metabolic bone diseases, engaged during dialysis, can be applied. It can increase the levels of serum calcium, can reduce levels of serum alkaline phosphatase and parathyroid hormone, improve radiological and histological sign of osteitis (with or without osteomalacia). Bone resorption, hyperparathyroidism and osteodystrophy signs of mineralization defects all can be reduced, as for osteomalacia patients and children who are unable to obtain sufficient bone development because of renal osteodystrophy or parathyroid dysfunction, may be more favorable than calcitriol. Such cases can be treated with Calcifediol and calcitriol. But as for osteomalacia accompanied by gastrointestinal diseases, Calcifediol is preferable. If because of liver disease to cause generated obstacles of 25-OHD in vivo, secondary osteomalacia, can also try to use this product. But osteomalacia caused by aluminum poisoning, treatment of vitamin D preparations often is ineffective. Chelator deferoxamine (Desferal) clear aluminum of blood dialysis, can be effective. Osteomalacia and rickets (in children causing deformities severe osteomalacia) is characterized by obstacle of bone mineralization and non-calcified bone-like tissue or cartilage accumulation. Bone changes of Vitamin D-related bone softening, accompanied with normal or reduced levels of serum calcium and phosphorus, increased serum alkaline phosphatase, and PTH is secondary increased. Osteoporosis is characterized by reduced bone tissue thereby increasing the likelihood of fractures. Pathological mechanism may be an increased rate of bone resorption, exceeding bone formation; or decreased bone formation, and bone resorption is also still normal or reduced. Bone is progressive missing, can compress and collapse the spine, causing pain, body shorter and kyphosis. Patients are also prone to the outer periphery fracture. The above information is edited by the chemicalbook of Liu Yujie. |
| Side effects and precautions |
Like all the vitamin D metabolites, excessive Calcifediol can also cause increased serum calcium, in urine can increase high. Therefore, in the dose adjustment period, serum calcium should be monitored at least once a week, if increased serum calcium was found, it should be discontinued. Pregnant women use this product, there is no adequately controlled studies, but in experimental animals, teratogenic effects have been found. The US Food and Drug Administration (FDA) classify the product into pregnancy category C drugs. People who use digitalis, should be used with caution vitamin D, because increased calcium may induce arrhythmia. Other side effects and precautions, see "Vitamin D2" (Vita-min D2) that is ergocalciferol. Action of Vitamin D2 is intense, may cause damage. Increased serum calcium caused by excess, can cause gastrointestinal and central nervous system lesions, soft tissue calcification. Kidney complications can be very serious and even cause death. Such as increased serum calcium persists, after discontinuation, kidney damage likely will continue for a long time. An individual who the amount is not too large, but also because of increased sensitivity to occur adverse reactions. Calcifediol is rapidly absorbed, at 4 to 8 hours up to serum peak concentration. Transport shall bind with protein, half-life is about 16 days. |
| Chemical Properties | White Solid |
| Usage | A metabolite of Vitamin D. The principal circulating form of vitamin D3, formed in the liver by hydroxylation at C-25. Calcium regulator. |
| CALCIFEDIOL Basic information |
| Product Name: | CALCIFEDIOL |
| Synonyms: | CALCIDIOL;25-HYDROXYVITAMIN D3;25-HYDROXYCHOLECALCIFEROL;VITAMIN D3, 25-HYDROXY-;25-HYDROXYVITAMIN D3 WHITE CRYSTALLINE SOLID 985;25-Hydroxyvitamin D3;vitamin d3 25-hydroxy monohydrate;(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol |
| CAS: | 19356-17-3 |
| MF: | C27H44O2 |
| MW: | 400.64 |
| EINECS: | 242-990-9 |
| Product Categories: | Vitamin D3 analogs;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Isolabel;Inhibitors |
| Mol File: | 19356-17-3.mol |
|
|
|
| CALCIFEDIOL Chemical Properties |
| mp | 74-76oC |
| Fp | 14 °C |
| storage temp. | −20°C |
| Safety Information |
| Hazard Codes | T+,F |
| Risk Statements | 28-48/25-26-24/25-11 |
| Safety Statements | 28-36/37-45-16-7 |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| F | 8-10-19 |
| MSDS Information |
| Provider | Language |
|---|---|
| SigmaAldrich | English |
| CALCIFEDIOL Usage And Synthesis |
| Therapeutic drug for bone disease |
The natural source of Vitamin D in the body depends on ultraviolet rays of sunlight, making the 7- dehydrocholesterol convert into vitamin D3, at first under the action of vitamin D3 hydroxylase in liver vitamin D3 converts into the Calcifediol, vitamin D3 mainly is present in the form of the Calcifediol in the blood, in the kidney the Calcifediol is further converted to 1,25-dihydroxyvitamin D3 (calcitriol for short) and 24,25-dihydroxyvitamin D3, activity of calcitriol is 2-5 times of the Calcifediol, the two drugs can promote bone re-absorption of calcium and intestinal absorption of Ca2 +. In addition to regulating the body's calcium and phosphorus metabolism, this product can promote the intestinal absorption of calcium and phosphorus, promote calcium and phosphorus deposits in the bone tissue, promote bone formation. Calcifediol itself has a certain activity, can be used for the treatment of metabolic bone diseases, such as osteoporosis, rickets, osteomalacia, but also for hemodialysis-induced hypocalcemia. Patients with chronic renal failure combined with metabolic bone diseases, engaged during dialysis, can be applied. It can increase the levels of serum calcium, can reduce levels of serum alkaline phosphatase and parathyroid hormone, improve radiological and histological sign of osteitis (with or without osteomalacia). Bone resorption, hyperparathyroidism and osteodystrophy signs of mineralization defects all can be reduced, as for osteomalacia patients and children who are unable to obtain sufficient bone development because of renal osteodystrophy or parathyroid dysfunction, may be more favorable than calcitriol. Such cases can be treated with Calcifediol and calcitriol. But as for osteomalacia accompanied by gastrointestinal diseases, Calcifediol is preferable. If because of liver disease to cause generated obstacles of 25-OHD in vivo, secondary osteomalacia, can also try to use this product. But osteomalacia caused by aluminum poisoning, treatment of vitamin D preparations often is ineffective. Chelator deferoxamine (Desferal) clear aluminum of blood dialysis, can be effective. Osteomalacia and rickets (in children causing deformities severe osteomalacia) is characterized by obstacle of bone mineralization and non-calcified bone-like tissue or cartilage accumulation. Bone changes of Vitamin D-related bone softening, accompanied with normal or reduced levels of serum calcium and phosphorus, increased serum alkaline phosphatase, and PTH is secondary increased. Osteoporosis is characterized by reduced bone tissue thereby increasing the likelihood of fractures. Pathological mechanism may be an increased rate of bone resorption, exceeding bone formation; or decreased bone formation, and bone resorption is also still normal or reduced. Bone is progressive missing, can compress and collapse the spine, causing pain, body shorter and kyphosis. Patients are also prone to the outer periphery fracture. The above information is edited by the chemicalbook of Liu Yujie. |
| Side effects and precautions |
Like all the vitamin D metabolites, excessive Calcifediol can also cause increased serum calcium, in urine can increase high. Therefore, in the dose adjustment period, serum calcium should be monitored at least once a week, if increased serum calcium was found, it should be discontinued. Pregnant women use this product, there is no adequately controlled studies, but in experimental animals, teratogenic effects have been found. The US Food and Drug Administration (FDA) classify the product into pregnancy category C drugs. People who use digitalis, should be used with caution vitamin D, because increased calcium may induce arrhythmia. Other side effects and precautions, see "Vitamin D2" (Vita-min D2) that is ergocalciferol. Action of Vitamin D2 is intense, may cause damage. Increased serum calcium caused by excess, can cause gastrointestinal and central nervous system lesions, soft tissue calcification. Kidney complications can be very serious and even cause death. Such as increased serum calcium persists, after discontinuation, kidney damage likely will continue for a long time. An individual who the amount is not too large, but also because of increased sensitivity to occur adverse reactions. Calcifediol is rapidly absorbed, at 4 to 8 hours up to serum peak concentration. Transport shall bind with protein, half-life is about 16 days. |
| Chemical Properties | White Solid |
| Usage | A metabolite of Vitamin D. The principal circulating form of vitamin D3, formed in the liver by hydroxylation at C-25. Calcium regulator. |